Chuanrui Xu

3.9k total citations · 1 hit paper
53 papers, 2.3k citations indexed

About

Chuanrui Xu is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Chuanrui Xu has authored 53 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Molecular Biology, 21 papers in Cancer Research and 11 papers in Oncology. Recurrent topics in Chuanrui Xu's work include MicroRNA in disease regulation (17 papers), RNA Interference and Gene Delivery (8 papers) and Cancer therapeutics and mechanisms (7 papers). Chuanrui Xu is often cited by papers focused on MicroRNA in disease regulation (17 papers), RNA Interference and Gene Delivery (8 papers) and Cancer therapeutics and mechanisms (7 papers). Chuanrui Xu collaborates with scholars based in China, United States and Netherlands. Chuanrui Xu's co-authors include Xingxing He, Ying Chang, Ju‐Sheng Lin, Dong Xu, Shuzhen Sun, Coral Ho, Zhiping Zhang, Susie A. Lee, Xin Chen and Guangya Xiang and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Gastroenterology and PLoS ONE.

In The Last Decade

Chuanrui Xu

51 papers receiving 2.3k citations

Hit Papers

Hepatogastroenterology 2012 2026 2016 2021 2012 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Hepatogastroenterology
    2012 835 citations Xingxing He, Ying Chang et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chuanrui Xu China 23 1.0k 552 542 478 333 53 2.3k
Xuyong Wei China 26 1.1k 1.0× 464 0.8× 408 0.8× 463 1.0× 201 0.6× 127 2.3k
Han Wu China 31 808 0.8× 330 0.6× 527 1.0× 625 1.3× 298 0.9× 92 2.5k
Masamichi Mizuma Japan 21 595 0.6× 560 1.0× 917 1.7× 370 0.8× 343 1.0× 130 1.9k
Guihua Chen China 29 1.7k 1.7× 390 0.7× 605 1.1× 910 1.9× 292 0.9× 85 3.2k
Xingxing He China 32 2.1k 2.1× 564 1.0× 600 1.1× 1.4k 2.9× 451 1.4× 80 3.9k
Yen‐Hua Huang Taiwan 26 957 0.9× 243 0.4× 346 0.6× 377 0.8× 168 0.5× 57 2.2k
Yu Yao China 23 701 0.7× 244 0.4× 909 1.7× 462 1.0× 452 1.4× 104 2.3k
Hui Tao China 35 1.8k 1.8× 374 0.7× 312 0.6× 793 1.7× 303 0.9× 123 3.2k
Ning Ding China 20 925 0.9× 243 0.4× 340 0.6× 170 0.4× 199 0.6× 57 2.0k
Nathalie Charnaux France 33 836 0.8× 195 0.4× 532 1.0× 324 0.7× 151 0.5× 78 2.8k

Countries citing papers authored by Chuanrui Xu

Since Specialization
Citations

This map shows the geographic impact of Chuanrui Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chuanrui Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chuanrui Xu more than expected).

Fields of papers citing papers by Chuanrui Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chuanrui Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chuanrui Xu. The network helps show where Chuanrui Xu may publish in the future.

Co-authorship network of co-authors of Chuanrui Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Chuanrui Xu. A scholar is included among the top collaborators of Chuanrui Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chuanrui Xu. Chuanrui Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Qi, et al.. (2025). Metabolic reprogramming in cholangiocarcinoma cancer stem cells: Emerging therapeutic paradigms. Cancer Letters. 622. 217714–217714. 1 indexed citations
2.
Zhang, Mi, Cheng‐Jie Yang, Jia‐Xuan Yan, et al.. (2023). Improved anti-tumor activity of fluorinated camptothecin derivatives 9-fluorocamptothecin and 7-ethyl-9-fluorocamptothecin on hepatocellular carcinoma by targeting topoisomerase I. Bioorganic Chemistry. 139. 106652–106652. 11 indexed citations
3.
Tan, Xuan, Kun Cai, Jiajia Li, et al.. (2023). Coronavirus subverts ER-phagy by hijacking FAM134B and ATL3 into p62 condensates to facilitate viral replication. Cell Reports. 42(4). 112286–112286. 33 indexed citations
4.
Xiang, Ming, Tingting Liu, Cheng Tian, et al.. (2022). Kinsenoside attenuates liver fibro-inflammation by suppressing dendritic cells via the PI3K-AKT-FoxO1 pathway. Pharmacological Research. 177. 106092–106092. 63 indexed citations
5.
Zhou, Yong, Mi Zhang, Jianmei Gao, et al.. (2022). Design and synthesis of Aza-boeravinone derivatives as potential novel topoisomerase I inhibitors. Bioorganic Chemistry. 122. 105747–105747. 5 indexed citations
6.
Yuan, Weigang, Mi Zhang, Chunxu Wang, et al.. (2022). Resveratrol Attenuates High-Fat Diet–Induced Hepatic Lipotoxicity by Upregulating Bmi-1 Expression. Journal of Pharmacology and Experimental Therapeutics. 381(2). 96–105. 17 indexed citations
7.
Zhang, Mi, Xiaofei Liu, Lei Li, et al.. (2022). Anti-tumor effects and mechanism of a novel camptothecin derivative YCJ100. Life Sciences. 311(Pt A). 121105–121105. 13 indexed citations
8.
Chen, Yuyuan, Bin Li, Xiao-Bo Zhao, et al.. (2021). Design and synthesis of novel 20(S)-α-aminophosphonate derivatives of camptothecin as potent antitumor agents. Bioorganic Chemistry. 114. 105065–105065. 8 indexed citations
9.
Tian, Cheng, et al.. (2020). The Role of CARD9 in Metabolic Diseases. Current Medical Science. 40(2). 199–205. 13 indexed citations
10.
Yang, Cheng‐Jie, Bin Li, Zhijun Zhang, et al.. (2019). Design, synthesis and antineoplastic activity of novel 20(S)-acylthiourea derivatives of camptothecin. European Journal of Medicinal Chemistry. 187. 111971–111971. 14 indexed citations
11.
Li, Bin, Yuyuan Chen, Fei Wang, et al.. (2019). Bmi1 drives hepatocarcinogenesis by repressing the TGFβ2/SMAD signalling axis. Oncogene. 39(5). 1063–1079. 22 indexed citations
12.
Che, Jing, Yu Huang, Chuanrui Xu, & Peng Zhang. (2017). Increased ceramide production sensitizes breast cancer cell response to chemotherapy. Cancer Chemotherapy and Pharmacology. 79(5). 933–941. 17 indexed citations
13.
Xue, Huiying, Yong Liu, Weigang Yuan, et al.. (2017). Delivery of miR-375 and doxorubicin hydrochloride by lipid-coated hollow mesoporous silica nanoparticles to overcome multiple drug resistance in hepatocellular carcinoma. International Journal of Nanomedicine. Volume 12. 5271–5287. 72 indexed citations
14.
He, Xingxing, Shuzhen Kuang, Jiazhi Liao, et al.. (2014). The regulation of microRNA expression by DNA methylation in hepatocellular carcinoma. Molecular BioSystems. 11(2). 532–539. 60 indexed citations
15.
Qi, Shibo, Bin Li, Yang Tan, et al.. (2014). Validation of Bmi1 as a Therapeutic Target of Hepatocellular Carcinoma in Mice. International Journal of Molecular Sciences. 15(11). 20004–20021. 9 indexed citations
16.
Guo, Yuanyuan, Songwei Tan, Shuang Zhao, et al.. (2013). Chitosan-g-TPGS Nanoparticles for Anticancer Drug Delivery and Overcoming Multidrug Resistance. Molecular Pharmaceutics. 11(1). 59–70. 129 indexed citations
17.
Xu, Chuanrui, Susie A. Lee, & Xin Chen. (2010). RNA Interference as Therapeutics for Hepatocellular Carcinoma. Recent Patents on Anti-Cancer Drug Discovery. 6(1). 106–115. 32 indexed citations
18.
Kosinski, Cynthia, Daniel E. Stange, Chuanrui Xu, et al.. (2010). Indian Hedgehog Regulates Intestinal Stem Cell Fate Through Epithelial−Mesenchymal Interactions During Development. Gastroenterology. 139(3). 893–903. 95 indexed citations
19.
Xu, Chuanrui, Coral Ho, Prashant Bommi, et al.. (2009). Bmi1 Functions as an Oncogene Independent of Ink4A/Arf Repression in Hepatic Carcinogenesis. Molecular Cancer Research. 7(12). 1937–1945. 59 indexed citations
20.
Patil, Mohini A., Susie A. Lee, Everardo Macias, et al.. (2008). Role of Cyclin D1 as a Mediator of c-Met– and β-Catenin–Induced Hepatocarcinogenesis. Cancer Research. 69(1). 253–261. 73 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xuyong Wei Breakdown of academic impact, for papers by Han Wu Breakdown of academic impact, for papers by Masamichi Mizuma Breakdown of academic impact, for papers by Guihua Chen Breakdown of academic impact, for papers by Xingxing He Breakdown of academic impact, for papers by Yen‐Hua Huang Breakdown of academic impact, for papers by Yu Yao Breakdown of academic impact, for papers by Hui Tao Breakdown of academic impact, for papers by Ning Ding Breakdown of academic impact, for papers by Nathalie Charnaux
Rankless by CCL
2026